Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 312486
1. Duque P, Oltra-Cucarella J, Fernandez O, Sepulcre J, Grupo de Estudio de la Bateria Neuropsicologica Breve En la Esclerosis Multiple GE: [Brief Neuropsychological Battery for multiple sclerosis. Normative data stratified by age and educational level]. Rev Neurol; 2017 Feb 01;64(3):97-104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brief Neuropsychological Battery for multiple sclerosis. Normative data stratified by age and educational level].
  • [Transliterated title] Bateria neuropsicologica breve en la esclerosis multiple. Baremacion normativa estratificada por edad y nivel educativo.
  • INTRODUCTION: Interpretation of the performance on cognitive tests for neuropsychological assessment in multiple sclerosis (MS) differs according to the educational level of the examinee.
  • AIMS: To provide normative data for the Brief Neuropsychological Battery (BNB) for MS stratified by age and education, as well as to demonstrate the utility of the battery for discriminating between healthy controls and patients with MS.
  • SUBJECTS AND METHODS: Data from 701 healthy volunteers from the original normative sample were stratified by age and education using regression analyses of standard scores.
  • Performance of the healthy control group was compared to a group of 112 patients with MS.
  • CONCLUSIONS: Our data indicate that the BNB for MS is sensitive for identifying cognitive impairments in MS, specifically in tasks measuring working memory.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28128426.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Cardamone G, Paraboschi EM, Rimoldi V, Duga S, Soldà G, Asselta R: The Characterization of GSDMB Splicing and Backsplicing Profiles Identifies Novel Isoforms and a Circular RNA That Are Dysregulated in Multiple Sclerosis. Int J Mol Sci; 2017 Mar 07;18(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Characterization of GSDMB Splicing and Backsplicing Profiles Identifies Novel Isoforms and a Circular RNA That Are Dysregulated in Multiple Sclerosis.
  • In particular, a growing body of evidence suggests the existence of a pathogenic association between a generalized defect in splicing regulatory genes and multiple sclerosis (MS).
  • Moreover, several studies have documented an unbalance in alternatively-spliced isoforms in MS patients possibly contributing to the disease etiology.
  • In this work, using a combination of PCR-based techniques (reverse-transcription (RT)-PCR, fluorescent-competitive, real-time, and digital RT-PCR assays), we investigated the alternatively-spliced gene encoding Gasdermin B, <i>GSDMB</i>, which was repeatedly associated with susceptibility to asthma and AIDs.
  • Importantly, both AS isoforms and the identified ecircRNA were significantly dysregulated in peripheral blood mononuclear cells of relapsing-remitting MS patients compared to controls, further supporting the notion that aberrant RNA metabolism is a characteristic feature of the disease.
  • [MeSH-major] Gene Expression Regulation. Multiple Sclerosis / genetics. Neoplasm Proteins / genetics. RNA. RNA Splicing
  • [MeSH-minor] Alternative Splicing. Case-Control Studies. Exons. Female. Gene Order. Humans. Male. Multiple Sclerosis, Relapsing-Remitting / blood. Multiple Sclerosis, Relapsing-Remitting / genetics. Nonsense Mediated mRNA Decay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Cell Immunol. 2016 Apr;7(2):402 [27375925.001]
  • [Cites] Biomed Rep. 2015 Mar;3(2):152-158 [25798239.001]
  • [Cites] Eur J Endocrinol. 2016 May;174(5):R225-38 [26628584.001]
  • [Cites] Genomics. 2007 May;89(5):618-29 [17350798.001]
  • [Cites] N Engl J Med. 2009 Jun 11;360(24):2544-55 [19458352.001]
  • [Cites] Genome Biol. 2015 Mar 25;16:58 [25885816.001]
  • [Cites] Int J Mol Sci. 2015 Dec 22;17 (1):null [26703587.001]
  • [Cites] Nucleic Acids Res. 2006 May 08;34(8):e63 [16682442.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] RNA Biol. 2010 Jul-Aug;7(4):462-73 [20639696.001]
  • [Cites] Cell. 2014 Sep 25;159(1):134-47 [25242744.001]
  • [Cites] Nat Commun. 2016 Nov 16;7:13426 [27848966.001]
  • [Cites] Int J Mol Sci. 2015 Sep 30;16(10):23463-81 [26437396.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):759-61 [11526377.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] Cell Rep. 2015 Jan 6;10(1):103-11 [25543144.001]
  • [Cites] EMBO J. 2013 Apr 3;32(7):923-5 [23463100.001]
  • [Cites] Genes Dev. 2014 Oct 15;28(20):2233-47 [25281217.001]
  • [Cites] Autoimmun Rev. 2014 Apr-May;13(4-5):518-24 [24424194.001]
  • [Cites] Nature. 2015 Oct 29;526(7575):666-71 [26375259.001]
  • [Cites] Transl Oncol. 2008 Jul;1(2):73-83 [18633457.001]
  • [Cites] Am J Cancer Res. 2016 Jun 01;6(6):1167-76 [27429839.001]
  • [Cites] BMC Genomics. 2013 Sep 17;14:627 [24044605.001]
  • [Cites] PLoS One. 2015 Oct 20;10(10):e0141214 [26485708.001]
  • [Cites] Cell Mol Neurobiol. 2016 Aug;36(6):865-72 [26768647.001]
  • [Cites] PLoS One. 2014 Mar 27;9(3):e90099 [24675552.001]
  • [Cites] Mol Immunol. 2015 Feb;63(2):521-9 [25458313.001]
  • [Cites] J Neuroimmunol. 2010 May;222(1-2):82-6 [20226540.001]
  • [Cites] Lancet Neurol. 2008 Dec;7(12):1078-9 [19007729.001]
  • [Cites] Genes Genet Syst. 2010 Feb;85(1):75-83 [20410667.001]
  • [Cites] PLoS Genet. 2013;9(9):e1003777 [24039610.001]
  • [Cites] RNA. 2014 Dec;20(12):1829-42 [25404635.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5015-8 [10799854.001]
  • [Cites] Nat Genet. 2009 Jun;41(6):703-7 [19430480.001]
  • [Cites] Front Genet. 2016 Apr 06;7:53 [27092176.001]
  • [Cites] Nat Rev Microbiol. 2009 Feb;7(2):99-109 [19148178.001]
  • [Cites] Oncogene. 2016 May 12;35(19):2413-27 [26300000.001]
  • [Cites] RNA. 2013 Feb;19(2):141-57 [23249747.001]
  • [Cites] Nat Rev Immunol. 2004 Dec;4(12):931-40 [15573128.001]
  • [Cites] PLoS One. 2009 Oct 13;4(10):e7440 [19823682.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] F1000Res. 2014 Jun 20;3:132 [25254102.002]
  • [Cites] J Pathol. 2010 Jan;220(2):152-63 [19918805.001]
  • [Cites] Genome Res. 2016 Sep;26(9):1277-87 [27365365.001]
  • [Cites] Cell Mol Life Sci. 2015 Dec;72(23):4523-44 [26283621.001]
  • [Cites] J Allergy Clin Immunol. 2004 Dec;114(6):1463-70 [15577853.001]
  • [Cites] Nature. 2013 Mar 21;495(7441):384-8 [23446346.001]
  • [Cites] Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13132-13137 [27799535.001]
  • [Cites] Mol Cell. 2014 Oct 2;56(1):55-66 [25242144.001]
  • [Cites] Clin Exp Immunol. 1998 Jul;113(1):96-9 [9697990.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Mar;48(3):261-71 [19051310.001]
  • [Cites] Cytokine. 2013 Mar;61(3):720-3 [23375120.001]
  • [Cites] Ann Allergy Asthma Immunol. 2012 Jun;108(6):402-411.e9 [22626592.001]
  • [Cites] Nature. 2016 Jul 7;535(7610):111-6 [27281216.001]
  • [Cites] EMBO Rep. 2008 Nov;9(11):1087-93 [18846105.001]
  • [Cites] Nature. 2015 Oct 29;526(7575):660-5 [26375003.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1413-5 [18978789.001]
  • [Cites] FASEB J. 1993 Jan;7(1):155-60 [7678559.001]
  • [Cites] Pathology. 2008 Jan;40(1):13-24 [18038310.001]
  • [Cites] Immunol Rev. 2011 Sep;243(1):163-73 [21884175.001]
  • [Cites] RNA. 2014 Nov;20(11):1666-70 [25234927.001]
  • [Cites] Mult Scler. 2004 Oct;10(5):482-7 [15471361.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Sep;6(5):660-4 [10473513.001]
  • [Cites] Mult Scler. 2006 Jun;12(3):294-301 [16764342.001]
  • [Cites] Genome Biol. 2014 Jul 29;15(7):409 [25070500.001]
  • [Cites] Int J Mol Sci. 2013 Aug 05;14(8):16087-110 [23921681.001]
  • [Cites] Hum Mol Genet. 2014 Dec 20;23(25):6746-61 [25080502.001]
  • (PMID = 28272342.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / GSDMB protein, human; 0 / Neoplasm Proteins; 0 / RNA, circular; 63231-63-0 / RNA
  • [Keywords] NOTNLM ; GSDMB / alternative splicing / circRNA / multiple sclerosis / nonsense-mediated mRNA decay
  •  go-up   go-down


3. Zare L, Sheikh Fathollahi M, Kazemi Arababadi M, Shamsizadeh A, Daneshpajouh B, Zainodini N, Allahtavakoli M: The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis. Iran Red Crescent Med J; 2016 Sep;18(9):e25995

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis.
  • BACKGROUND: Multiple Sclerosis (MS) is a common autoimmune system disease which affects the central nervous system.
  • It has been documented that interleukin-25 (IL-25) plays key roles in suppressing Th1 responses, which is increased during MS.
  • OBJECTIVES: The aim of this study was to investigate the c424C/A polymorphism within the IL-25 gene in MS patients in comparison to healthy controls.
  • PATIENTS AND METHODS: In this case-control study, 74 patients with MS and 75 healthy controls were selected.
  • Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was used in order to determine c424C/A polymorphism within the IL-25 gene.
  • RESULTS: The results showed that there was no statistical significant difference in distribution of genotype (AA, AC and CC) and allele (A and C) frequencies between MS patients and healthy controls (P = 0.901 and P = 0.728, respectively).
  • CONCLUSIONS: In conclusion, it appears that the c424C/A polymorphism within the IL-25 gene has no significant relationship with MS, and this polymorphism is probably not associated with MS complications, its onset and gender distribution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28144453.001).
  • [ISSN] 2074-1804
  • [Journal-full-title] Iranian Red Crescent medical journal
  • [ISO-abbreviation] Iran Red Crescent Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Keywords] NOTNLM ; CCL25 / Genetic / Multiple Sclerosis / Polymorphism
  •  go-up   go-down


Advertisement
4. Passerini G, Dalla Costa G, Sangalli F, Moiola L, Colombo B, Locatelli M, Comi G, Furlan R, Martinelli V: Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. Mult Scler Int; 2016;2016:2303857

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis.
  • The presence of CSF oligoclonal bands (OBs) is an independent prognostic factor for multiple sclerosis (MS), but the difficulties in the standardization of the test and the interlaboratory variation in reporting have contributed to its limited use in the diagnosis of the disease.
  • The presence of OBs, kappa and lambda FLC levels, and standard indices of intrathecal inflammation were assessed in 100 consecutive patients, including patients with MS, clinically isolated syndromes (CIS), other inflammatory diseases of the CNS, and other noninflammatory diseases. <i>Results</i>.
  • KFLC and LFLC were significantly different in patients with MS and CIS compared to the other groups (<i>p</i> < 0.001 and <i>p</i> < 0.001, resp.) and had a better diagnostic accuracy than all the other tests (area under the curve 82.3 % for KFLC index and 79.3 % for LFLC index). <i>Conclusion</i>.
  • Nephelometric assays for KFLC in CSF reliably detect intrathecal immunoglobulin synthesis and discriminate MS patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 2014 Nov 15;276(1-2):175-9 [25146968.001]
  • [Cites] J Clin Immunol. 2005 Jul;25(4):338-45 [16133990.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902 [8057110.001]
  • [Cites] J Neuroimmunol. 2010 Feb 26;219(1-2):1-7 [19782408.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Eur J Neurol. 2005 Jul;12(7):527-30 [15958092.001]
  • [Cites] Neurology. 2008 Mar 25;70(13 Pt 2):1079-83 [17881717.001]
  • [Cites] Scand J Clin Lab Invest. 1977 Sep;37(5):385-90 [337459.001]
  • [Cites] PLoS One. 2014 Apr 02;9(4):e88680 [24695382.001]
  • [Cites] Mult Scler. 2016 Apr;22(4):502-10 [26199348.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14 [23431079.001]
  • [Cites] Neurology. 2012 Mar 13;78(11):823-32 [22411958.001]
  • [Cites] PLoS One. 2014 Feb 25;9(2):e89945 [24651567.001]
  • [Cites] Mult Scler. 2015 Jul;21(8):967-8 [26041796.001]
  • [Cites] J Neurol Sci. 2001 Mar 1;184(2):101-22 [11239944.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2009 Mar;80(3):292-6 [18829628.001]
  • [Cites] Ann Neurol. 1985 Jan;17(1):21-7 [3985581.001]
  • [Cites] J Neurol. 2016 May;263(5):954-60 [26995358.001]
  • [Cites] Nat Rev Neurol. 2013 May;9(5):267-76 [23528543.001]
  • [Cites] J Immunol Methods. 2011 Aug 31;371(1-2):170-3 [21704629.001]
  • [Cites] J Neuroimmunol. 2015 Dec 15;289:62-7 [26616872.001]
  • [Cites] J Neuroimmunol. 2013 Oct 15;263(1-2):116-20 [23916392.001]
  • [Cites] J Neurol. 2008 Oct;255(10):1508-14 [18685917.001]
  • [Cites] J Clin Epidemiol. 2005 Oct;58(10):982-90 [16168343.001]
  • (PMID = 28116160.001).
  • [ISSN] 2090-2654
  • [Journal-full-title] Multiple sclerosis international
  • [ISO-abbreviation] Mult Scler Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


5. Farrokhi M, Masoudifar A, Derakhshan A, Saadatmand S, Rouhi-Boroujeni H, Etemadifar M, Rezaei-Zarji S, Javid A, Nobakht R, Deyhimi M, Ekramnia A, Ebrahimi M, Sheikh S, Ansaripour S, Amani-Beni A, Jahanbani-Ardakani H: The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis. Immunol Invest; 2017 Feb 02;:1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis.
  • BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS) that is immunologically mediated in genetically susceptible individuals.
  • Single-nucleotide polymorphisms (SNPs) in the IL-16 gene may lead to altered cytokine expression or biological activity, and these variations may modulate an individual's risk for MS.
  • To test this hypothesis, we investigated association of IL-16 gene SNPs (i.e., rs4072111 C/T, rs11556218 G/T, and rs4778889 C/T) and serum IL-16 levels with risk of MS in an Iranian population.
  • METHODS: We analyzed the three SNPs of IL-16 in 250 MS patients and 400 healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • The serum level of IL-16 was assessed by enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The IL-16 rs4072111C/T genotype and allele frequencies showed significantly differences between MS patients and controls (p < 0.01).
  • The mean serum levels of IL-16 in MS patients were significantly higher in MS patients compared to healthy controls (p ≤ 0.01).
  • CONCLUSION: In summary, the present study provides the first evidence that the rs11556218T/G and rs4072111C/T polymorphisms of IL-16 gene were significantly associated with increased risk of MS.
  • These results suggest that rs11556218T/G, rs4072111C/T, and rs4778889T/C polymorphisms of IL-16 may contribute to susceptibility to MS through increased expression of IL-16 levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151028.001).
  • [ISSN] 1532-4311
  • [Journal-full-title] Immunological investigations
  • [ISO-abbreviation] Immunol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ELISA / interleukin-16 / multiple sclerosis / polymerase chain reaction / polymorphism
  •  go-up   go-down


6. Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO: Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clin Pharmacokinet; 2017 03 02;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
  • METHODS: This population PK analysis was based on the combined dataset from four clinical studies in patients with multiple sclerosis (MS): three phase I studies, including one food and one drug-drug interaction study, and one phase III clinical study.
  • RESULTS: The analysis comprised a total of 2619 CdA and CAde plasma and urine concentration observations from 173 patients with MS who received an intravenous infusion or oral tablet doses of CdA as a single agent or in combination with interferon (IFN) β-1a.
  • CdA renal clearance (CL<sub>R</sub>) was correlated with creatinine clearance (CL<sub>CR</sub>), predicting a decrease in the total clearance of 19%, 30% and 40% for patients with mild (CL<sub>CR</sub> = 65 ml/min), moderate (CL<sub>CR</sub> = 40 ml/min) and severe (CL<sub>CR</sub> = 20 ml/min) renal impairment, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28255849.001).
  • [ISSN] 1179-1926
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00213135
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Liu G, Hu Y, Jin S, Jiang Q: Genetic variant rs763361 regulates multiple sclerosis CD226 gene expression. Proc Natl Acad Sci U S A; 2017 Feb 07;114(6):E906-E907

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variant rs763361 regulates multiple sclerosis CD226 gene expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82 [27162345.001]
  • [Cites] Nat Genet. 2012 Oct;44(10):1084-9 [22941192.001]
  • [Cites] Nature. 2013 Sep 26;501(7468):506-11 [24037378.001]
  • [Cites] PLoS Genet. 2011 Aug;7(8):e1002197 [21829388.001]
  • [Cites] Genes Immun. 2009 Jan;10(1):5-10 [18971939.001]
  • [Cites] PLoS Biol. 2008 Dec 23;6(12):e1 [19222302.001]
  • [Cites] Nat Neurosci. 2014 Oct;17(10):1418-28 [25174004.001]
  • [Cites] Genome Res. 2011 Jul;21(7):1008-16 [21602305.001]
  • [Cites] Nat Genet. 2013 Oct;45(10):1238-43 [24013639.001]
  • [Cites] Science. 2015 May 8;348(6235):648-60 [25954001.001]
  • (PMID = 28137889.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


8. Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR: Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis. Data Brief; 2017 Apr;11:364-370

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis.
  • The data presented in this article are related to the research article entitled "The autoimmune risk gene ZMIZ1 is a vitamin D responsived marker of a molecular phenotype of multiple sclerosis" Fewings et al. (2017) [1].
  • Here we identify the set of genes correlated with ZMIZ1 in multiple cohorts, provide phenotypic details on those cohorts, and identify the genes negatively correlated with ZMIZ1 and the cells predominantly expressing those genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] Hum Mol Genet. 2014 Mar 15;23 (6):1425-34 [24158849.001]
  • [Cites] Hum Mol Genet. 2013 Oct 15;22(20):4194-205 [23748426.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Clin Immunol. 2016 Feb;163:96-107 [26762769.001]
  • [Cites] J Autoimmun. 2017 Mar;78:57-69 [28063629.001]
  • [Cites] Clin Immunol. 2014 Mar;151(1):16-24 [24495857.001]
  • [Cites] Ann Neurol. 2011 Dec;70(6):881-6 [22190362.001]
  • [Cites] Hum Mol Genet. 2010 Jun 1;19(11):2134-43 [20190274.001]
  • [Cites] Nat Genet. 2013 Nov;45(11):1353-60 [24076602.001]
  • [Cites] Mult Scler. 2014 May;20(6):675-85 [24126065.001]
  • (PMID = 28275670.001).
  • [Journal-full-title] Data in brief
  • [ISO-abbreviation] Data Brief
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS088155
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Gene expression / Molecular phenotype / Multiple sclerosis / ZMIZ1
  •  go-up   go-down


9. Galea MP, Cofré Lizama LE, Butzkueven H, Kilpatrick TJ: Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤ 3.0. NeuroRehabilitation; 2017;40(2):277-284

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤ 3.0.
  • BACKGROUND AND PURPOSE: It is not currently known whether gait and balance measures are responsive to deterioration of motor function in multiple sclerosis (MS) patients with low EDSS scores (≤3.0).
  • The aim of this study was to quantify MS-related gait and balance deterioration over a 12-month period.
  • METHODS: Thirty-eight participants with MS (33 female, mean age: 41.1 ± 8.3 years), mean time since diagnosis 2.2 ± 4.1 years, EDSS score ≤3.0 and without clinical evidence of gait deterioration, were recruited.
  • Kinematics of the ankle and knee, and electromyography of the tibialis anterior and medial gastrocnemius muscles were also measured.
  • RESULTS: Three participants reported relapses with worsening EDSS scores and 4 non-relapsing participants had worse EDSS scores at 12 months.
  • There were significant decreases in mean gait speed, stride length and balance scores, and a significant increase in double support.
  • Marked changes in ankle kinematics, with decreased medial gastrocnemius activity were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28222549.001).
  • [ISSN] 1878-6448
  • [Journal-full-title] NeuroRehabilitation
  • [ISO-abbreviation] NeuroRehabilitation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Gait / balance / multiple sclerosis
  •  go-up   go-down


10. Abdollah Zadeh R, Jalilian N, Sahraian MA, Kasraian Z, Noori-Daloii MR: Polymorphisms of RPS6KB1 and CD86 associates with susceptibility to multiple sclerosis in Iranian population. Neurol Res; 2017 Mar;39(3):217-222
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of RPS6KB1 and CD86 associates with susceptibility to multiple sclerosis in Iranian population.
  • OBJECTIVE:  Multiple sclerosis (MS) is the most prevalent disorder of nervous system inflammation which involves demyelination of spinal cord; this process depends on both environmental and genetic susceptibility factors.
  • In the present study, we examined the association between two SNPs in RPS6KB1 (rs180515) and CD86 (rs9282641) with MS in Iranian population.
  • RPS6KB1gene encodes p70S6K1 protein which plays a key role in mTOR signaling pathway, while CD86 gene codes a membrane protein type I which belongs to immunoglobulin super family act on co-stimulation signaling pathway.
  • METHODS: In this case-control study 130 patients with MS and 128 matched healthy controls were enrolled, genomic DNA was isolated and genotyping was performed using mismatched PCR-RFLP.
  • For this variation, AA genotype was shown to have protective effect (P = 0.016 and OR = 0.6), while GG genotype was a susceptive genotype to MS (P = 0.04 and OR = 2.2).
  • CONCLUSION: We successfully replicated the association of two novel SNPs introduced by a GWAS study, and MS in the Iranian population.
  • This result can open ways for better understanding the mechanisms involved in MS.
  • [MeSH-major] Antigens, CD86 / genetics. Multiple Sclerosis / genetics. Ribosomal Protein S6 Kinases, 70-kDa / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Female. Genetic Predisposition to Disease. Genome-Wide Association Study. Humans. Iran. Male. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • Genetic Alliance. consumer health - Multiple sclerosis susceptibility.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28079472.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD86; 0 / CD86 protein, human; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.1 / ribosomal protein S6 kinase, 70kD, polypeptide 1
  • [Keywords] NOTNLM ; CD86 polymorphism / MS / PCR- RFLP / RPS6KB1 polymorphism / multiple sclerosis
  •  go-up   go-down






Advertisement